NCT05053802招募中2 期
Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial
Shanghai Pulmonary Hospital, Shanghai, China6 个研究点 分布在 1 个国家目标入组 146 人开始时间: 2021年3月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 146
- 试验地点
- 6
- 主要终点
- Progression-free rate of remaining lesions
研究概览
简要总结
Prospective, multi-center, phase II clinical trial. The study plans to enroll 146 patients with multiple lung cancers. After signing the informed consent, they were screened to meet the admission and discharge criteria, and received microwave ablation treatment. Electromagnetic navigation bronchoscope-guided intrapulmonary microwave ablation or percutaneous microwave ablation was selected according to the patient's wishes and the evaluation of the surgeon. After the operation, they were randomized and the experimental group accepted PD-1 immune checkpoint inhibitor treatment (microwave ablation combined with Camrelizumab treatment does not exceed 16 cycles, or disease progression/worsening or confirmed imaging disease progression, or withdrawal for any reason), the control group does not After receiving any treatment, the two groups were followed up closely (36 months after the last treatment, including safety follow-up and survival follow-up).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18～79 years old;
- •Multiple pulmonary nodules diagnosed by CT, the number of target lesions ≥2 and ≤5 (definition of target lesions: the largest diameter of a single nodule ≥8 mm or the largest diameter of a solid component ≥5mm, and the largest single nodule Diameter ≤30 mm), the target lesions are distributed in at least two lung lobes;
- •The target lesions need to be pathologically indicated as lung cancer, and at least one of the target lesions is pathologically diagnosed as lung cancer (at least one target lesion is pathologically diagnosed as lung cancer, and the CT follow-up after anti-inflammatory treatment for the remaining target lesions is clear and stable for no less than 3 months, which is also consistent with the entry Group conditions);
- •The patient has no lymph node metastasis, lung metastasis or distant organ metastasis (N0, M0);
- •ECOG PS score 0-2;
- •Expected survival time ≥ 12 months;
- •Sufficient hematology function, defined as absolute neutrophil count ≥1.5×109/L, platelet count ≥80×109/L, hemoglobin ≥90g/L (no history of blood transfusion within 7 days, no G-CSF and others Correction of hematopoietic stimulating factors);
- •Sufficient liver function, defined as all patients with total bilirubin level ≤1.5 times upper limit of normal (ULN) and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤2.5 times ULN;
- •Sufficient renal function, defined as creatinine clearance ≥50ml/min (Cockcroft-Gault formula);
- •The coagulation function is adequate, defined as the international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 times ULN; if the subject is receiving anticoagulation therapy, as long as the INR/PT is within the proposed range of anticoagulation drugs Can;
- •For female subjects of childbearing age, the urine or serum pregnancy test should be negative within 3 days before receiving the first study drug administration. If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required;
- •If there is a risk of conception, male and female patients need to use high-efficiency contraception (that is, a method with a failure rate of less than 1% per year) and continue until at least 180 days after stopping the trial treatment;
- •Subjects voluntarily join the study and sign written informed consent before any trial-related procedures are implemented. They have good compliance and cooperate with follow-up.
排除标准
- •Genetic testing is positive for at least one mutation of EGFR, ALK, ROS1 fusion, BRAF V600E mutation, and NTRK fusion;
- •Pulmonary nodules with the largest diameter> 30mm in preoperative imaging examination;
- •Preoperative imaging examination or mediastinal lymph node puncture indicates patients with positive preoperative lymph nodes;
- •Patients with distant metastasis or chest or ascites found in preoperative examination;
- •Currently participating in interventional clinical research treatment, or receiving treatment with other research drugs or research devices within 3 months before the first intervention;
- •Any systemic anti-tumor treatment before tumor ablation, including interventional chemoembolization, radiotherapy, chemotherapy, targeted therapy, or Chinese patent medicine with anti-tumor indications or immunomodulatory drugs (thymosin, interferon, interleukin, etc.) ), or received major surgery within 3 weeks before the first intervention;
- •Have received the following therapies in the past: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or drugs that stimulate or synergistically inhibit T cell receptors (for example, CTLA4, OX-40, CD137);
- •There are multiple factors that affect surgery or ablation (such as coagulation dysfunction, immune system disease, etc.);
- •Abnormal coagulation function (PT>16 s, APTT>43 s, TT>21 s, Fbg< 2 g/L), bleeding tendency (such as active peptic ulcer) or receiving thrombolytic or anticoagulant therapy;
- •Pulmonary hemorrhage ≥ CTCAE grade 2 occurred within 4 weeks before the first intervention; other parts of hemorrhage ≥ CTCAE grade 3 occurred within 4 weeks before treatment;
- •Known history of human immunodeficiency virus (HIV) infection (ie HIV 1/2 antibody positive), known syphilis infection (syphilis antibody positive), active tuberculosis, active hepatitis without treatment;
- •People with severe impairment of heart, liver, and kidney functions (heart function grades 3 to 4, ALT and/or AST are more than 3 times the upper limit of normal, and Cr exceeds the upper limit of normal);
- •Known mental illness or drug abuse that may affect compliance with test requirements;
- •Patients with other malignant tumors or hematological diseases;
- •Pregnant, planned pregnancy and breast-feeding female patients (when urine HCG>2500IU/L, it is diagnosed as early pregnancy);
- •The investigator believes that it is not suitable for inclusion.
结局指标
主要结局
Progression-free rate of remaining lesions
时间窗: 5 years
1 Year Recurrence-free survival
时间窗: 1 year
3 Year Recurrence-free survival
时间窗: 3 years
次要结局
- 2 Year Recurrence-free survival(2 years)
- 5 Year Recurrence-free survival(5 years)
- 3 year overall survival(3 years)
- 5 year overall survival(5 years)
- Quality of life score(4 years)
- Complication rate(3 years)
研究者
Chang Chen
Shanghai Pulmonary Hospital
Shanghai Pulmonary Hospital, Shanghai, China
研究点 (6)
Loading locations...
相似试验
尚未招募
2 期
A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid TumorsSolid TumorNCT06537505Beidahuang Industry Group General Hospital60
Unknown
2 期
Microwave Ablation Combined With Chemotherapy in the Treatment of Pancreatic Cancer Oligohepatic MetastasisPancreatic Cancer Metastatic to LiverOligometastasisNCT04677192Fudan University50
已完成
不适用
Comparison of Response and Recurrence Rates Following Percutaneous Microwave Coagulation Therapy Versus Percutaneous Radiofrequency AblationThermoablationChronic Liver DiseaseHepatocellular CarcinomaNCT02859753Centre Hospitalier Universitaire Dijon35
已完成
不适用
Clinical Feasibility of Microwave Ablation Using Two Channel Microwave Generator and Two Antennas for Small Hepatocellular CarcinomaHepatocellular CarcinomaNCT06086002Seoul National University Hospital20
招募中
不适用
Microwave Ablation in the Treatment of Early-stage Unifocal Invasive Breast CancerBreast CancerNCT06288620The First Affiliated Hospital with Nanjing Medical University77